Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant androgen deprivation plus high-dose 3D conformal radiotherapy in intermediate- or high-risk localized prostate cancer
2005-000417-36Phase 3Active
- Sponsor
- Dra. Almudena Zapatero Laborda
- Start
- May 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Dra. Almudena Zapatero Laborda. Primary endpoint: Biochemical failure-free survival at 5 years. Started May 2006; status: active.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2005-000417-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000417-36.